Cocrystal pharma presents phase 1 results for pan-viral inhibitor cdi-988 at department of defense medical conference

All cdi-988 doses, ranging from 100 mg to 1200 mg, in the phase 1 study were well tolerated company expects to initiate phase 1b study with cdi-988 in norovirus-infected healthy subjects later this year lack of approved norovirus treatments or vaccines creates critical unmet medical need bothell, wash., aug. 05, 2025 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) announces the presentation of favorable safety and tolerability data from a randomized, double-blinded, placebo-controlled phase 1 study with its oral, direct-acting pan-viral inhibitor cdi-988 at the 2025 military health system research symposium (mhsrs), being held august 4-7 in kissimmee, florida.
COCP Ratings Summary
COCP Quant Ranking